Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis

Abstract

Chronic skin inflammatory diseases including atopic dermatitis (AD) and psoriasis have been considered uncontrolled inflammatory responses, which have usually troubled patients around the world. Moreover, the recent method to treat AD and psoriasis has been based on the inhibition, not regulation, of the abnormal inflammatory response, which can induce a number of side effects and drug resistance in long-term treatment. Mesenchymal stem/stromal cells (MSCs) and their derivatives have been widely used in immune diseases based on their regeneration, differentiation, and immunomodulation with few adverse effects, which makes MSCs a promising treatment for chronic skin inflammatory diseases. As a result, in this review, we aim to systematically discuss the therapeutic effects of various resources of MSCs, the application of preconditioning MSCs and engineering extracellular vesicles (EVs) in AD and psoriasis, and the clinical evaluation of the administration of MSCs and their derivatives, which can provide a comprehensive vision for the application of MSCs and their derivatives in future research and clinical treatment.

Etanercept-synthesizing adipose-derived stem cell secretome: A promising therapeutic option for inflammatory bowel disease

“…Recent advances in cell biology and regenerative medicine have positioned the cell-derived secretome and extracellular vesicles at the forefront of therapeutic interventions, especially concerning inflammatory and infectious diseases. Stem cell-derived secretomes inherently possess anti-inflammatory and immunomodulatory properties, which offer promise in conditions like rheumatoid arthritis[ 1 ], autoimmune diseases[ 2 ], skin allergies[ 3 , 4 ], and various infectious diseases[ 5 , 6 ]. However, the characteristics of the secretome are not fixed but are instead influenced by the environmental and genetic conditioning of the donor cells[ 7 ].…”

Comparative Study of Hematological Parameters and Biomarkers of Immunity and Inflammation in Patients with Psoriasis and Atopic Dermatitis

“…Chronic skin inflammatory diseases, such as atopic dermatitis (AD) and psoriasis (PsO) are related to the imbalance between anti-inflammatory and pro-inflammatory mediators in favor of the latter ones [ 1 ]. Despite their chronic and pro-inflammatory nature, these diseases have some differences in their pathogenesis.…”

“…The abnormal T helper 2 (Th2) lymphocyte activation with consequent secretion of a variety of pro-inflammatory cytokines, such as interleukin (IL)-4, IL-5, IL-22, etc., that further leads to the destruction of epidermal barrier is suggested as the underlying pathological mechanism of AD [ 1 ]. On the other hand, the activation of abnormal Th1 and Th17 lymphocytes with concomitant secretion of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-17, IL-23, etc.…”

“…On the other hand, the activation of abnormal Th1 and Th17 lymphocytes with concomitant secretion of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-17, IL-23, etc. is assumed to be the pathological mechanism of PsO [ 1 ].…”